II. Indications: Atrial Fibrillation Cardioversion
- Time to Cardioversion: 1 hour
- Conversion Rate: 33-45% (60% in Atrial Flutter)
III. Mechanism
- Class III Antiarrhythmic
IV. Dose
- Initial
- Under 60 kg: 0.01 mg/kg IV over 10 min
- Over 60 kg: 1 mg IV over 10 min
- Subsequent
- May repeat once after 10 min if not converted
V. Adverse Effects
- Observe QT Interval
- Evaluate Serum Potassium and Magnesium
- Significantly proarrhythmic
- Ventricular Tachycardia or fibrillation risk: 1-2%
- Requires EKG monitoring for 4 hours after dose
VI. Precautions
- Most expensive Antiarrhythmic
- Cardiac monitor on starting agent
- Continue for minimum of 4 hours
- Continue until QT Interval normalizes
Images: Related links to external sites (from Bing)
Related Studies
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C067192 |
| SnomedCT | 108491000, 372500009 |
| English | ibutilide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide, ibutilide [Chemical/Ingredient], IBUTILIDE, Ibutilide (product), Ibutilide (substance), Ibutilide |
| Spanish | ibutilida (producto), ibutilida (sustancia), ibutilida |
Ontology: Corvert (C0644117)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C067192 |
| English | Pfizer brand of ibutilide fumarate, Corvert |
